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Rheumatoid arthritis and multiple sclerosis: Direful siblings, different strategiesBased on their severity and chronicity, rheumatoid arthritis
(RA) and multiple sclerosis (MS) are the most disabling autoim-
mune diseases in humans. However, RA and MS also represent
excellent examples to understand the communication between
the central nervous system (CNS) and the immune system. In RA,
breach in immune tolerance results in peripheral autoimmune dis-
ease, which in consequence profoundly affects the CNS via neuro-
immune mechanisms [1]. On the other hand, breach in immune
tolerance in MS directly leads to inﬂammation in the CNS, which
then results in the dysfunction of peripheral organs.
Despite affecting entirely different target tissues, which are the
synovial membrane in RA and the glia in MS, RA and MS share
common principles: (i) Their etiopathogenesis is incompletely
understood, although recent ﬁndings have corroborated the
hypothesis that both emerge from tight interplay between genetic
susceptibility, such as HLDR alleles in RA and MS as well as e.g.,
PTPN22 variants in RA and interleukin-7 variants in MS, and envi-
ronmental factors like smoking and infections [2–4]. (ii) RA and MS
share common pathophysiology, which is a chronic inﬂammatory
process based on enhanced migration of innate and adaptive im-
mune cells including macrophages and neutrophils as well as T
and B lymphocytes into the target tissues, which is then followed
by cytokine, chemokine and matrix enzyme production allowing
to perpetuate the inﬂammatory process [5,6]. (iii) Inﬂammation
in RA and MS is followed by tissue destruction leading to irrevers-
ible loss of function of the involved organ. Ironically both RA and
MS lead to loss of locomotor function, MS by the destruction of
the neuronal capacity allowing muscle innervation, RA by directly
destroying the cartilage, bones, tendons and ligaments required for
locomotion. In fact, aside the inhibition of inﬂammation, preserva-
tion of function is considered being a key therapeutic goal of ther-
apy in both RA and MS. (iv) Substantial progress has been achieved
to develop selective therapeutic interventions in RA and MS, which
have not only fostered the therapeutic armamentarium in addition
to long-existing broad-spectrum anti-inﬂammatory (e.g., glucocor-
ticoids) and immunosuppressive agents (e.g., methotrexate and
azathioprine) but also allowed to identify key molecular and cellu-
lar mechanisms of the disease processes in RA and MS.
Despite shared principles in the etiopathogenesis, pathophysi-
ology and therapeutic approaches there are substantial differences
between RA and MS, which become particularly apparent when
taking a closer look to the major therapeutic targets in the two
diseases. Tumor necrosis factor alpha (TNFa) inhibitors have
become a mainstay of therapy in RA, as these agents rapidly and
permanently inhibit inﬂammation in RA [7]. In sharp contrast,0014-5793/$36.00  2011 Federation of European Biochemical Societies. Published by E
doi:10.1016/j.febslet.2011.10.030TNFa inhibitors do not affect inﬂammation in MS but even precip-
itate ﬂares leading to contraindication of use in MS patients [8].
This observation still seeks mechanistic explanation but suggests
that inﬂammatory disease processes in RA and MS are profoundly
different. In contrast to RA, where three therapeutic principles
(TNFa-, IL-1-, and IL-6R- blockade) are based on cytokine inhibi-
tion, the blockade of inﬂammatory cytokines plays no major role
in the therapy of MS to date and vice versa substitution of cytokine
such as IFNb is only affecting MS but not RA [5,9]. Furthermore,
effective strategies to interfere with T cell mediated autoimmunity
in RA and MS are substantially different. Thus, the principle to
block co-stimulation of T cells is only used in RA but not in MS,
whereas MS responds well to interference with T cell migration
such as the blockade of alpha-4-integrin (by natalizumab) as well
as sphingosin-1-phosphate analogues blocking migration of T cells
from lymph nodes to inﬂammatory sites (ﬁngolimod) [10,11].
Interestingly, more speciﬁc antigen-based immune interventions,
like a random polymer of four amino acids found in myelin basic
protein (glatiramer), have so far only been successful in MS but
not in RA.
It is thus of seminal importance to understand why there are
fundamental differences between RA and MS and how these differ-
ences shed light on speciﬁc pathophysiological principles of these
two major autoimmune diseases. There is no doubt that RA and
MS are based on systemic autoimmunity, which leads to local
inﬂammation and damage in a selected target tissue. The dilemma
to explain organ tropism of systemic autoimmunity is still one of
the major unanswered questions of autoimmune disease. Compar-
ing new mechanistic insights obtained in RA and MS as shown in
the following focus issue may help to solve this problem.
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